Hormone Sensitive Prostate Cancer Market

Hormone Sensitive Prostate Cancer Market: Global Industry Analysis and Opportunity Assessment 2016-2026

  • Ongoing
  • April 2020
  • REP-GB-1375
Hormone Sensitive Prostate Cancer Market

  • US$5,000
  • US$7,500
  • US$10,000

This Hormone Sensitive Prostate Cancer market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Hormone Sensitive Prostate Cancer market.

Prostate cancer is a general term used for diseased condition in which abnormal cells grow and invade in uncontrolled manner in the prostate. Prostate cancer inhibits production of male sex hormones (i.e. androgens) and ultimately blocks the action of androgen. The androgen is also responsible for the growth of prostate cancer. Androgen binds with the receptors and stimulates the expression of specific genes that would be responsible for prostate cancer. However, androgen suppression hormonal therapies are commonly used for the treatment of this cancer. These therapies acts by reducing the production of androgen by the testicles or by blocking the action of androgen in the body. There is an opportunity for the growth of hormone sensitive prostate cancer owing to the rapidly aging population which is the major cause of prostate cancer.

Hormone Sensitive Prostate Cancer Market: Drivers and Restraints

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Need granular data and specific insights that are hard to get?
Increasing incidence of hormone sensitive prostate cancers and availability of various treatment modalities like surgery, radiation therapy and cryosurgery are the major factors driving the growth of hormone sensitive prostate cancer treatment market globally. The driving factor of hormone sensitive prostate cancer market is the. Advancement in technology, personalized medicine, cost effective treatment procedures are few other factors expected provide boost to global hormone sensitive prostate cancer treatment market. However, limited commercially availability drugs and treatments for this cancer is the challenge restraining the growth of global hormone sensitive prostate cancer treatment market.

Hormone Sensitive Prostate Cancer Market: Segmentation

The global hormone sensitive prostate cancer market has been segmented on the basis of treatment, end use and geography.

Hormone Sensitive Prostate Cancer Market: Overview

Androgen ablation therapy are generally known as the first line of treatment and thus expected to hold maximum revenue share in overall hormone sensitive prostate cancer treatment market. Anti-androgens and GnRH antagonists are usually prescribed for long term which is also expected to surge the market of hormone sensitive prostate cancer.  The increasing incidences of prostate cancer cases increases the demand of hormonal therapies during the forecast period and hence promotes the market growth.

Hormone Sensitive Prostate Cancer Market: Regional Overview

Geographically, the global hormone sensitive prostate cancer market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.North America takes the largest share of global hormone sensitive cancer treatment market followed by Europe. The global hormone sensitive prostate cancer treatment market is expected to grow in future due to increasing investment by multinational companies in cancer research.

Hormone Sensitive Prostate Cancer Market: Key Players

Some of the key players in hormone sensitive prostate cancer market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers, Dendreon Corporation, GlaxoSmithKline plc., Ferring International Center S.A., Roche group, Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Bayer AG, and Pfizer Inc.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Hormone Sensitive Prostate Cancer Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Based on treatment, the global hormone sensitive prostate cancer market is segmented into:

  • Androgen Ablation Therapy
  • Anti-androgens
  • Chemotherapy
  • Targeted Therapy
  • Cryotherapy

Based on end user type, the global hormone sensitive prostate cancer market is segmented into:

  • Hospitals
  • Clinics
  • Cancer Rehabilitation Centers

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
  • Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
  • Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC, S. Africa, Rest Of MEA)

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Hormone Sensitive Prostate Cancer Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Hormone Sensitive Prostate Cancer Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields
Our Clients

Request Sample Request customization Request Methodology